Dr Ed Wild of UCL Huntington’s Disease Centre (Institute of Neurology) delivers an update on Ionis Pharmaceuticals 443139-CS1 trial, testing HTTRx, a huntingtin-lowering antisense oligonucleotide or ‘gene silencing’ drug in Huntington’s disease patients.